Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Marginal Zone Lymphoma
Regimen:
(cyclophosphamide + prednisone + Rituxan (rituximab) + vincristine)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
ESMO.org
Title:
Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Published date:
01/06/2020
Excerpt:
Summary of recommendations: Chemoimmunotherapy is recommended in patients with NMZL (e.g. R-bendamustine, R-CHOP, R-CVP) [IV, B].
DOI:
10.1016/j.annonc.2019.10.010
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
NCCN
Excerpt:
Marginal Zone Lymphoma: Second-Line and subsequent therapy...CVP (cyclophosphamide, vincristine, prednisone) + Rituximab
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login